Trial Profile
Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 11 Oct 2016 Results assessing plasma YKL-40 as a biomarker, presented at the 41st European Society for Medical Oncology Congress
- 14 Jun 2011 New trial record